GermanyGermany

New OECD-compatible data for German biotech companies

08.06.2009

Berlin – According to the latest figures from biotechnologie.de, Germany’s biotech sector has grown in the last year. A survey conducted by the information platform received an 85% response rate from the German bio­tech companies taking part. It revealed that turnover among the country’s 500 dedicated companies climbed 9?% to over a2bn in 2008, while R&D expenditure remained stable at approximately a1bn (+1.1%). The number of staff employed rose slightly. The survey was conducted on behalf of the German Research Ministry in early 2009. In compliance with the guidelines laid out by the Organisation for Economic Co-operation and Development (OECD), the study was conducted to help provide insights into the economic situation of the German bio-

tech landscape.

Importance of biotechnology

on the rise

The study identified a total of 500 companies in Germany that dealt either exclusively or predominantly with biotechnological procedures. These companies had 14,450 employees on their books (compared to 14,360 in 2007).
The importance of the field is also increasing in companies where biotechnology is just one business activity among others, according to the study. In the 92 companies that fell into this category – among them pharma firms, chemical enterprises, and seed manufacturers – 15,520 people were employed in bio­tech-related areas. That brings the total number of staff employed in commercial biotechnology in Germany to about 30,000, 1.4?% more than in 2007.

A maturing market

The average German biotech company is 8.6 years old. Roughly a third have been active for more than 10 years, whereas just 13% were founded in the last 3 years.
Many of the respondents set up shop in the wake of the 1996 Bio­Regio competition (1997-2001). About 60% of all biotech companies still operating today began their business activities during this period. The competition is also still visible in the current distribution of companies. Three of Germany’s four largest biotechnology clusters are located in the winning regions of the funding contest that was initiated by former German Research Minister Jürgen Rüttgers, are still booming. The Munich area and Rhineland/Cologne region were at the top of the list, along with Berlin-Brandenburg and Baden-Wurttemberg (see figure).
Most of the other companies active in the sector are situated in the federal states of North Rhine-Westphalia, Hessen and Lower Saxony, reflecting the strong industrial focus of the western part of the country.

GermanyGermany

27.10.2011

Leverkusen - Bayer Pharma has a lucky streak. The pharma division of the German chemical giant announced positive Phase III results from regorafenib in colorectal cancer. “We are extremely encouraged by the result of this...

GermanyGermany

24.10.2011

Leverkusen - A short statement from the European Medicines Agency (EMA) and a big step for the German biotech Biofrontera. The agency issued a favourable opinion on Biofrontera's marketing approval application for its drug for...

GermanyGermany

14.10.2011

Leverkusen/San Francisco - Bayer HealthCare and Onyx Pharmaceuticals will not to court over Nevaxar. The two companies reached an agreement related to regorafenib, a late-stage oncology compound. Regorafenib is an oral...

GermanyGermany

11.10.2011

Ingelheim/Ridgefield –Boehringer Ingelheim’s COPD treatment Combivent Respimat has been approved by the U.S. Food and Drug Administration (FDA) for the US market. The new, propellant-free inhaler product for the beta adrenergic...

GermanyGermany

01.10.2011

Rostock – German researchers say overexpression of one of the 49 transport proteins that shuttle substances over the blood-brain barrier could be the key to treating Alzheimer’s disease. In mice, the group headed by Jens Pahnke...

GermanyGermany

27.09.2011

Rehovot/Monheim – Bayer Crop Science may be a step closer to introducing desirable traits in wheat. In the collaboration with Israeli Evogene Ltd. the German company has reached a milestone. Utilising Evogene‘s proprietary...

GermanyGermany

22.09.2011

Willich – Brasilian biopolymer producer Braskem and German bioplastics compounding specialist FKuR GmbH, have signed a compounding agreement for green polyethylene. The tailor-made product will be a first in Europe, according...

GermanyGermany

08.09.2011

Leverkusen - It was a black Tuesday for Bayer. After rumours were leaked out that the FDA has doubts over the German pharmaceutical company's potential blockbuster Xarelto, the shares temporarily dropped as much as 17 percent....

GermanyGermany

06.09.2011

Bad Homburg - German VC firm Creathor venture announced the first closing of its Creathor Venture Fund III. Now, the company is poised to mete out €51million of fresh capital to start-ups. Life science companies will be among the...

Displaying results 21 to 30 out of 454

< Previous 21-30 Next >

© 2007-2014 BIOCOM

http://www.european-biotechnology-news.com/nc/news/messages-archive/archive-germany/browse/2/article/new-oecd-compatible-data-for-german-biotech-companies.html

Print Magazine

Product of the week

Products

Events

All Events

Partner-Events

Stock list

All quotes

TOP

  • 4SC0.94 EUR2.17%
  • ACTELION108.70 CHF0.00%
  • ADDEX3.07 CHF0.00%

FLOP

  • CYTOTOOLS31.45 EUR-0.47%
  • ACTELION108.70 CHF0.00%
  • ADDEX3.07 CHF0.00%

TOP

  • CYTOS0.28 CHF64.7%
  • EPIGENOMICS5.15 EUR47.1%
  • STRATEC BIOMEDICAL48.50 EUR26.5%

FLOP

  • BIOFRONTERA2.52 EUR-13.7%
  • CO.DON2.51 EUR-11.6%
  • ADDEX3.07 CHF-9.7%

TOP

  • SANTHERA91.30 CHF2585.3%
  • CO.DON2.51 EUR139.0%
  • BB BIOTECH181.25 EUR63.4%

FLOP

  • CYTOS0.28 CHF-91.8%
  • 4SC0.94 EUR-46.0%
  • MOLOGEN7.35 EUR-41.4%

No liability assumed, Date: 21.11.2014

Current issue

All issues